CJC-1295 / Ipamorelin
GHRH Analog + GH Secretagogue Research Blend
Also referenced as: CJC-1295 (no DAC) + Ipamorelin Blend · Modified GRF 1-29 + Ipamorelin · GHRH Analog + GH Secretagogue Stack
≥99% Release Requirement
Full Panel COA
Free Shipping At $125+
Shipping Protection
Lab Results
| Test | Result | Status |
|---|---|---|
| Purity | – | Pending |
| Quantitation (Avg) | – | Pending |
| Heavy Metals (ICP-MS) | – | Pending |
| Endotoxin (USP <85>) | – | Pending |
| Rapid Microbial Screen | – | Pending |
| Multi Vial Tested | – | Pending |
Curated research on CJC-1295 / Ipamorelin
Jette L (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology.
PMID: 15817669 →Soule S (1994). Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men J Clin Endocrinol Metab.
PMID: 7962295 →Raun K (1998). Ipamorelin, the first selective growth hormone secretagogue Eur J Endocrinol.
PMID: 9849822 →Andersen NB (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats Growth Horm IGF Res.
PMID: 11735244 →
About CJC-1295 / Ipamorelin
A two-peptide research blend combining CJC-1295 without DAC (Modified GRF 1-29, 5mg) and Ipamorelin (5mg) in a single 10mg lyophilized vial. The blend pairs a growth-hormone-releasing hormone (GHRH) analog with a selective growth-hormone secretagogue, two complementary pathways studied in preclinical research on somatotroph signaling and growth-hormone release.
CJC-1295 (no DAC) is a tetra-substituted analog of GRF(1-29) that engages the GHRH receptor on anterior-pituitary cells, while Ipamorelin is a pentapeptide agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). The blend combines these two research compounds into a single formulation for laboratory studies of the GHRH and ghrelin-receptor pathways at the cellular level.
Also Referenced As
CJC-1295 (no DAC) + Ipamorelin Blend · Modified GRF 1-29 + Ipamorelin · GHRH Analog + GH Secretagogue Stack
Sourced through an established North American supply partner that conducts onsite manufacturer reviews against documented cGMP practices and applicable ISO quality criteria. Virtus Peptides tracks the factory batch number on every lot and catalogues it against independent lab testing, with a final Certificate of Analysis from ILS Laboratories. We pay more to source this way because we hold ourselves to a rigorous, documented standard for the product and for you.
Specifications
- Scientific Name
- CJC-1295 (Modified GRF 1-29) + Ipamorelin: Two-Peptide Research Blend
- CAS Number
- 446036-97-1 / 170851-70-4
- Molecular Formula
- CJC-1295 C₁₅₂H₂₅₂N₄₄O₄₂ · Ipamorelin C₃₈H₄₉N₉O₅
- Molecular Weight
- Blend: CJC-1295 (no DAC) 3,367.9 g/mol · Ipamorelin 711.9 g/mol
- Physical Form
- Lyophilized powder
- Purity
- Coming Soon
- Storage
- −20°C, protected from light, avoid repeated freeze-thaw cycles
Storage & Handling
Store per the product label and available manufacturer handling documentation, and follow standard laboratory protocols for handling.
Storage
Store the lyophilized powder at −20°C in a standard laboratory freezer, protected from light, moisture, and heat. Avoid repeated freeze-thaw cycles.
Shelf Life
Per the manufacturer, the lyophilized powder remains stable for 12–24 months when stored frozen in its original sealed vial. Our release testing verifies identity, purity, content, and the contaminant panels and does not itself establish shelf life.
Mechanism & Research Background
This blend supplies 10mg total per vial: CJC-1295 without DAC (Modified GRF 1-29, 5mg) and Ipamorelin (5mg). Each component has been independently characterized in research literature across two complementary growth-hormone-axis pathways: the GHRH receptor and the ghrelin / growth-hormone-secretagogue receptor.
CJC-1295 (no DAC) is a 29-amino-acid analog of human GRF(1-29), the shortest fully active fragment of native GHRH. It carries four substitutions, notably D-Ala at position 2, studied in vitro for increased resistance to dipeptidyl-peptidase-IV (DPP-IV) cleavage. In cultured somatotroph models the GHRH receptor (a class-B GPCR) couples to Gs / adenylyl cyclase, raising cAMP and activating PKA / CREB signaling associated with growth-hormone gene expression. Unlike the DAC-conjugated version, the no-DAC form lacks the albumin-binding linker and is studied as a short-acting GRF analog.
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide of the growth-hormone-secretagogue class that acts in vitro as a selective agonist of GHS-R1a, the receptor for endogenous ghrelin. In characterization work it was described as the first selective secretagogue, stimulating growth-hormone release in pituitary-cell and animal models without significantly elevating ACTH, cortisol, or prolactin above baseline. The blend combines these two research compounds in a single formulation; products supplied by Virtus Peptides are for in vitro laboratory research use only, not for human or veterinary use, not for diagnostic, therapeutic, or clinical use, and not intended for consumption or administration.
